Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $22.60 +2.31%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $23.00 (from $20.00) while maintaining a Perform rating.
You May Also Be Interested In
- Citi Upgrades The Macerich Company (MAC) to Buy
- ChargePoint Holdings Inc. (CHPT) PT Raised to $8 at UBS as Cost Discipline Improves
- Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
